Humacyte, Inc. (HUMA)
0.6852
-0.02
(-2.28%)
USD |
NASDAQ |
Aug 26, 16:00
0.6852
0.00 (0.00%)
After-Hours: 20:00
Humacyte Total Liabilities (Quarterly) : 106.83M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 106.83M |
| March 31, 2026 | 98.93M |
| December 31, 2025 | 113.26M |
| September 30, 2025 | 96.26M |
| June 30, 2025 | 134.74M |
| March 31, 2025 | 126.51M |
| December 31, 2024 | 190.54M |
| September 30, 2024 | 178.48M |
| June 30, 2024 | 166.57M |
| March 31, 2024 | 135.31M |
| December 31, 2023 | 114.68M |
| September 30, 2023 | 112.39M |
| Date | Value |
|---|---|
| June 30, 2023 | 106.99M |
| March 31, 2023 | 101.09M |
| December 31, 2022 | 87.37M |
| September 30, 2022 | 107.55M |
| June 30, 2022 | 104.10M |
| March 31, 2022 | 160.58M |
| December 31, 2021 | 164.36M |
| September 30, 2021 | 227.50M |
| June 30, 2021 | 16.81M |
| March 31, 2021 | 17.26M |
| December 31, 2020 | 36.02M |
| September 30, 2020 | 1.967M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Amgen, Inc. | 83.95B |
| Altimmune, Inc. | 53.00M |
| Protalix Biotherapeutics, Inc. | 38.93M |
| Taysha Gene Therapies, Inc. | 83.17M |
| Agenus, Inc. | 378.54M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 138.09M |
| Shareholders Equity (Quarterly) | 31.26M |
| Debt to Equity Ratio | 2.117 |
| Current Ratio | 6.207 |
| Net Debt Paydown Yield | 1.48% |